Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Cardiology/Vascular Diseases Phase I
Switzerland 
Details:
NI006 adds a novel and complementary approach to AstraZeneca and Alexion’s pipeline of investigational therapies focused on amyloidosis and strengthens the Company’s broader commitment to addressing cardiomyopathies that can lead to heart failure (HF).
Lead Product(s): NI006
Therapeutic Area: Cardiology/Vascular Diseases Product Name: NI006
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: $760.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration March 01, 2022
Details:
Under the agreement, Alexion will be granted an exclusive worldwide licence to develop, manufacture and commercialise NI006. NI006, an ATTR depleter, a novel and complementary approach to AstraZeneca and Alexion’s pipeline of investigational therapies focused on amyloidosis.
Lead Product(s): NI006
Therapeutic Area: Cardiology/Vascular Diseases Product Name: NI006
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $760.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration January 07, 2022
Details:
Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics and exploratory efficacy of NI006 in patients with wild-type and hereditary forms of ATTR cardiomyopathy.
Lead Product(s): NI006
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
